Thank you for your interest

Listen to the Podcast below

CHI interviews Dr. Xavier Jacq, Head of Biology at MISSION Therapeutics regarding drugging deubiquitinase enzymes (DUBs), a rapidly emerging target class within the Ubiquitin Proteasome System (UPS). Discussion topics and questions include:

• Tell us a little about MISSION and your current programs.
• Why are DUBs emerging as viable therapeutic targets?
• What are drug discovery challenges in this space? What about inhibitor discovery, how challenging is this?
• What might be challenges surrounding translating these compounds into the clinic?
• What are some novel tools and technologies being developed to overcome some of these challenges?
• You are giving a lecture at the 13th Annual Discovery on Target Conference, during the Targeting the Ubiquitin Proteasome System meeting. What do you hope to convey to attendees during your lecture this fall?
• How have you seen this field evolve over the past few years, and where do you see it going in the future?